Related Experiment Videos
Iseganan HCl: a novel antimicrobial agent.
Francis J Giles1, Rebecca Redman, Salim Yazji
1The University of Texas, MD Anderson Cancer Center, Department of Leukaemia, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA. fgiles@mdanderson.org
Expert Opinion on Investigational Drugs
|August 2, 2002
Summary
Iseganan HCl, an antimicrobial peptide, effectively prevents and reduces oral mucositis in patients undergoing chemotherapy and stem cell transplants. This novel antimicrobial is well-tolerated and shows promise for other infections.
Area of Science:
- Antimicrobial Peptides
- Clinical Pharmacology
- Oncology Supportive Care
Background:
- Oral mucositis (OM) is a debilitating side effect of cancer therapies, impairing local and systemic host defenses.
- Iseganan HCl possesses broad-spectrum bactericidal activity, stability in biological fluids, and no observed resistance, making it suitable for compromised host conditions.
Purpose of the Study:
- To evaluate the efficacy and safety of Iseganan HCl for the prevention and amelioration of oral mucositis.
- To explore other potential applications of Iseganan HCl in managing infections.
Main Methods:
- Clinical trials involving patients receiving stomatotoxic chemotherapy followed by hematopoietic stem cell transplant.
- Topical oral administration of Iseganan HCl.
Main Results:
- Iseganan HCl significantly reduced the occurrence of oral mucositis.
- It also ameliorated associated symptoms like mouth pain, throat pain, and dysphagia.
- The agent was well-tolerated with no systemic absorption observed.
Conclusions:
- Iseganan HCl is a promising therapeutic agent for preventing and managing oral mucositis in cancer patients.
- Its favorable safety profile and broad antimicrobial activity suggest potential for other indications, including ventilator-associated pneumonia and cystic fibrosis lung infections.